Loading
Loading
Research Overview
GLP-1 and glucagon dual receptor agonist similar to survodutide; activates energy expenditure through glucagon receptor-mediated thermogenesis while reducing caloric intake via central GLP-1 signalling.
Overview
Mazdutide (IBI362) is a synthetic peptide designed to act as a dual agonist at GLP-1 and glucagon receptors. Laboratory investigations have examined its activity profile across in vitro receptor binding assays and animal model systems, focusing on hepatic lipid biology and metabolic regulation.
In preclinical research, mazdutide has been studied for its effects on hepatic triglyceride content and circulating lipid fractions. Animal model studies have examined whether the glucagon receptor component contributes to increased lipolysis and altered fatty acid oxidation in liver tissue.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, mazdutide (glp-1/glucagon dual agonist) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
GLP-1 and glucagon dual receptor agonist similar to survodutide; activates energy expenditure through glucagon receptor-mediated thermogenesis while reducing caloric intake via central GLP-1 signalling.
Support
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.